Boehringer Ingelheim Corporation to Present Highly Anticipated Data From Landmark Tiospir™ Trial, and Their Respiratory Pipeline Products in COPD, Asthma, IPF and Lung Cancer at ERS 2013
9/3/2013 7:30:40 AM
or media outside the UK, US and Canada
•Results of COPD Phase III landmark trial TIOSPIR™ comparing safety and efficacy of SPIRIVA® Respimat® versus SPIRIVA® HandiHaler®
•Phase III trial results on investigational compound olodaterol* Respimat® as once-daily maintenance bronchodilator monotherapy in COPD
Help employers find you! Check out all the jobs and post your resume.
comments powered by